Content area

|
|

Kombinationsbehandling med thyroxin og trijodthyronin til patienter med hypotyreose

Forfatter(e)

Birte Nygaard1, Michael E. Røder2, Jesper Karmisholt3 & Jette Kolding Kristensen4

1) Endokrinologisk Sektion, Medicinsk Afdeling, Herlev og Gentofte Hospital 2) Medicinsk Afdeling, Herlev og Gentofte Hospital 3) Endokrinologisk Afdeling, Medicinerhuset, Aalborg Universitetshospital 4) Center for Forskning og Uddannelse i Almen Medicin, Klinisk Institut, Aalborg Universitet Ugeskr Læger 2018;180:V04170328

Reference: 
Ugeskr Læger 2018;180:V04170328
Blad nummer: 
Sidetal: 
2-5
Combination therapy of thyroxine and triiodothyronine in hypothyroid patients

Decreased quality of life is described more often in hypothyroid patients, who are treated with a synthetic form of thyroxine (L-T4), than in euthyroid controls. A combination of L-T4 and a synthetic form of triiodothyronine (L-T3) has been suggested; however, previous meta-analyses on unselected patients did not find any effect. Recent studies demonstrate, that the overall hypothalamic-pituitary-thyroid-tissue homeostasis could be more complex than previously suggested. Polymorphisms in deiodinase and thyroid hormone transporter genes could theoretically explain, why a minor subgroup of hypothyroid patients seem to have an effect of L-T4/L-T3 combination therapy.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Jesper Andreas Evers Palshof | 17/11
9 kommentarer
af Peter Søndergaard | 17/11
1 Kommentar
af Tom Nygaard Kristensen | 16/11
1 Kommentar
af Susanne Udengaard Gydesen | 16/11
6 kommentarer
af Lars Otto Hutters | 16/11
2 kommentarer
af Mette Cathrine Lauridsen | 16/11
2 kommentarer
af Peter Tagmose Thomsen | 09/11
1 Kommentar